References
- Cortes JE, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2019;94:346–357.
- Lipton J, Bryden P, Sidhu MK. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leuk Res. 2015;39:58–64.
- Lipton JH, Chuah C, Guerci-Bresler A, et al. Epic: a phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2014;124:519.
- Boddu Pl, Jain P, Borthakur G, et al. Outcomes of patients with chronic phase CML after discontinuation of frontline ponatinib therapy. Leuk Lymphoma. 2019;60:3172–3180.
- Latifi Y, Moccetti F, Wu M, et al. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood. 2019;133:1597–1606.
- Hamadi A, Grigg A, Dobie G, et al. Ponatinib tyrosine kinase inhibitor induces a thromboinflammatory response. Thromb Haemost. 2019;119(07):1112–1123.
- Cortes JE, Kim DW, Pinala Ibarz JL, et al. Ponatinib efficacy and safety in Philadelphia chromosome positive leukemia: final 5-year results of the phase 2 Pace trial. Blood. 2018;132:393–404.
- Dorer D, Knickerbocker R, Baccarini M, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84–91.
- Matteo M, Scalzulli E, Colafigli G. Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukemia. Ther Adv Haematol. 2019;10:1–14.
- Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17–23.
- Rea D, Tulliez M, Guilhot F, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129:846–854.
- Hirt C, Jannazzo S, Chiroli S, et al. Cost effectiveness of the third-generation tyrosine kinase inhibitor (TKI) ponatinib vs second-generation TKIS or stem cell transplant, as third-line treatment for chronic-phase chronic myeloid leukemia. Appl Health Econ Health Policy. 2019;17(4):555–567.